News
STAT+: AstraZeneca invests $2 billion in Summit Therapeutics
AstraZeneca is teaming up with Summit Therapeutics to test its PD-1/VEGF bispecific ivonescimab alongside AstraZeneca’s antibody-drug conjugates.
More in Health
- Tell us: have you had the shingles vaccine in the hope of reducing your dementia risk? The Guardian — Society
- Tennessee's failed execution ignites a medical ethics debate NPR — Health
- New NHS-style social care system could take decades, Dilnot says BBC News — Health
- Pennsylvania Measles Outbreak Grows to Nearly 900 Cases The New York Times — Health
- WHO Director-General visits Jordan to recognize strong collaboration on health system delivery, emergency relief and advancing mental health World Health Organization